

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee Jan 2019 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
1	Alectinib	Alecensa	Malignant disease and immunosuppression	Approved in principle	N/A
2	Asunaprevir	Sunvepra	Infections	pending	Pending further information
3	Daclatasvir	Daklinza	Infections	pending	Pending further information
4	Carboxymethylcellulose sodium	Refresh Plus	Eye	Approved	N/A
5	Ceftolozane/tazobactam	Zerbaxa	Infections	Approved	N/A
6	Dabrafenib	Tafinlar	Malignant disease and immunosuppression	Approved	N/A
7	Trametinib	Mekinist	Malignant disease and immunosuppression	Approved	N/A
8	Dulaglutide	Trulicity	Endocrine system	Approved	N/A
9	Edoxaban	Lixiana	Cardiovascular system	Approved	N/A
10	Eltrombopag	Revolade	Nutrition and blood	pending	Pending further information
11	Everolimus	Afinitor	Malignant disease and immunosuppression	Approved	N/A
12	Ipilimumab	Yervoy	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
13	Nivolumab	Opdivo	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient Lack of high quality level of evidence to demonstrate its efficacy
14	Lurasidone	Latuda	Central nervous system	Approved	N/A
15	Mepolizumab	Nucala	Respiratory system	Approved	N/A
16	Paclitaxel albumin	Abraxane	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
17	Pasireotide	Signifor LAR	Malignant disease and immunosuppression	Approved	N/A
18	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved in principle	N/A
19	Pomalidomide	Pomalyst	Malignant disease and immunosuppression	Approved	N/A

20	Sarilumab	Kevzara	Musculoskeletal and joint disease	Approved	N/A
21	Silodosin	Urief	Obstetrics, gynaecology, and urinary-tract disorders	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
22	Tafluprost eye drop preservative free	Taflotan-S	Eye	pending	Pending further information
23	Tenofovir alafenamide	Vemlidy	Infections	Approved	N/A
24	Tocilizumab	Actemra	Musculoskeletal and joint disease	Approved	N/A
25	Ustekinumab	Stelara	Gastro-intestinal system	Approved	N/A

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.